Bridge Biotherapeutics Inc Ordinary Shares 288330
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 288330 is a good fit for your portfolio.
News
-
Bridge Biotherapeutics Launches a Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade
-
Bridge Biotherapeutics Announces a Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology
Trading Information
- Previous Close Price
- KRW 2,115.00
- Day Range
- KRW 2,050.00–2,325.00
- 52-Week Range
- KRW 2,050.00–—
- Bid/Ask
- KRW 2,325.00 / KRW 2,330.00
- Market Cap
- KRW 54.50 Bil
- Volume/Avg
- 1.2 Mil / 662,186
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 424.45
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Bridge Biotherapeutics Inc is a drug research and development company. It operates in the pharmaceutical and bio industry. The company has two pipeline clinical-stage products namely, BBT-401 and BBT-877.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 40
- Website
- http://www.bridgebiorx.com
Comparables
Valuation
|
Metric
|
288330
|
310210
|
323990
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 8.69 | 7.81 | 4.52 |
Price/Sales | 424.45 | 730.35 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
288330
310210
323990
Financial Strength
|
Metric
|
288330
|
310210
|
323990
|
|---|---|---|---|
Quick Ratio | 2.01 | 4.85 | 54.78 |
Current Ratio | 2.09 | 4.91 | 55.43 |
Interest Coverage | −253.85 | −18.54 | −260.75 |
Quick Ratio
288330
310210
323990
Profitability
|
Metric
|
288330
|
310210
|
323990
|
|---|---|---|---|
Return on Assets (Normalized) | −81.65% | −42.78% | −29.47% |
Return on Equity (Normalized) | −168.76% | −96.10% | −30.90% |
Return on Invested Capital (Normalized) | −99.03% | −44.97% | −33.70% |
Return on Assets
288330
310210
323990
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vpfrtrzsz | Bdhg | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vtlswpy | Typpht | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rlbznzzpj | Ngdcfb | $97.3 Bil | |
MRNA
| Moderna Inc | Xkntsxd | Vwv | $41.3 Bil | |
ARGX
| argenx SE ADR | Tpcxlqmv | Qwpc | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Xrjjgcjrj | Gwktn | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Syvyjtrh | Hrzfnp | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Twgzhzsj | Hjfqqpb | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Svymbrrdc | Tjqhvnw | $12.6 Bil | |
INCY
| Incyte Corp | Nmrtdrhmt | Cglxlnq | $11.6 Bil |